First Tracks Biotherapeutics Inc TRAX 深 沪
等待开盘 11-05 09:30:00 美东时间
49.04
+2.700
+5.83%
华盛通- 最 高50.17
- 今 开48.01
- 成交量 93.95万股
- 最 低 46.09
- 昨 收 46.34
- 总市值 17.61亿
- 52周最高 50.17
- 市盈率 静 --
- 换手率 2.62%
- 52周最低 14.72
- 委 比 0.00%
- 总股本 3590.98万
- 历史最高 50.17
- 量 比 1.97
- 振 幅 8.80%
- 历史最低 14.72
- 每 手 1
- 风险率 11.20%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Guggenheim Maintains Buy on First Tracks, Raises Price Target to $110
Guggenheim analyst Yatin Suneja maintains First Tracks (NASDAQ:TRAX) with a Buy and raises the price target from $100 to $110.
11-04 23:11
财报速睇 | First Tracks Biotherapeutics Inc 2026财年Q3归母净利润亏损3.14亿美元，同比亏损缩窄25.1%
华盛资讯11月4日讯，First Tracks Biotherapeutics Inc公布2026财年Q3业绩，公司Q3归母净利润亏损3.14亿美元，同比亏损缩窄25.1%。
11-04 07:18
财报速睇 | First Tracks Biotherapeutics Inc 2026财年Q3归母净利润亏损3.14亿美元，同比亏损缩窄25.1%
华盛资讯11月4日讯，First Tracks Biotherapeutics Inc公布2026财年Q3业绩，公司Q3归母净利润亏损3.14亿美元，同比亏损缩窄25.1%。
11-04 05:35
美股牛股 | Bumble暴涨49.6%，传洽谈10亿美元私有化交易；Fair Isaac涨10.8%，裁员15%推进AI重组
Bumble暴涨49.6%，传洽谈10亿美元私有化交易；Fair Isaac涨10.8%，裁员15%推进AI重组
10-13 16:23
Why Is First Tracks Biotherapeutics Stock Soaring Monday?
First Tracks Biotherapeutics, Inc. (NASDAQ:TRAX) on Monday released topline results from Cohort 1 of its Phase 1b clinical trial of ANB033 in celiac disease. Following the announcement, the stock jumped more than 13%. The clinical-stage biotechnology firm designed ANB033 as an investigational, subcu...
10-12 20:23
First Tracks Biotherapeutics' ANB033 Demonstrates Statistically Significant Histologic And Symptom Benefits In Phase 1b Celiac Disease Trial
ANB033 achieved a statistically significant and clinically meaningful protective effect on both gluten-induced intestinal damage and symptoms LS mean change from baseline in Vh:Cd ratio of -0.17 on ANB033 vs. -0.66 on placebo, a +0.49 placebo-adjusted delta (p=0.009) LS mean change from baseline in ...
10-12 19:04
美股夜盘 | First Tracks Biotherapeutics Inc暴升15.16%，最新股价36.68美元
First Tracks Biotherapeutics Inc暴升15.16%，报36.68美元
10-12 11:27
美股大行评级 | 潜在涨幅600.93%！Ascendiant Capital上调Aytu BioPharma目标价至15美元，维持"买入"评级
今日重点评级关注：Ascendiant Capital：维持Aytu BioPharma"买入"评级，目标价从14.5美元升至15美元；摩根大通：维持Annexon"超配"评级，目标价从14美元升至15美元
10-01 19:18
Canaccord Genuity Initiates Coverage On First Tracks with Buy Rating, Announces Price Target of $50
Canaccord Genuity analyst Edward Nash initiates coverage on First Tracks (NASDAQ:TRAX) with a Buy rating and announces Price Target of $50.
09-30 19:36
